Biogen Inc. (NASDAQ:BIIB) Files An 8-K Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure

On November 7, 2017, Biogen Inc. (the “Company”) reported that, as of September 30, 2017, approximately 200 spinal muscular atrophy (“SMA”) patients have participated in the Company’s U.S. based clinical studies of SPINRAZA® (nusinersen) and approximately an additional 1,200 SMA U.S. patients have started on therapy in the post marketing setting, of which, approximately two-thirds are individuals with Type 2 or Type 3 SMA.

The information contained in Item 7.01 of this Current Report on Form 8-K is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act.

About Biogen Inc. (NASDAQ:BIIB)

Biogen Inc., formerly Biogen Idec Inc., is a biopharmaceutical company. The Company operates in discovering, developing, manufacturing and delivering therapies to patients for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders segment. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for multiple sclerosis (MS), ELOCTATE for hemophilia A and ALPROLIX for hemophilia B, and FUMADERM for the treatment of severe plaque psoriasis. It also has a collaboration agreement with Genentech, Inc., a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin’s lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL and follicular lymphoma, and other potential anti-CD20 therapies. It also develops late stage product candidates, including Aducanumab (BIIB037) for the treatment of Neurodegeneration, and Nusinersen for other programs.